Matthew Emmens - Net Worth and Insider Trading

Matthew Emmens Net Worth

The estimated net worth of Matthew Emmens is at least $99 Million dollars as of 2025-04-28. Matthew Emmens is the Director of Vertex Pharmaceuticals Inc and owns about 200,873 shares of Vertex Pharmaceuticals Inc (VRTX) stock worth over $99 Million. Details can be seen in Matthew Emmens's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew Emmens has not made any transactions after 2012-11-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of Matthew Emmens

To

Matthew Emmens Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew Emmens owns 3 companies in total, including Bristol-Myers Squibb Co (BMY) , Vertex Pharmaceuticals Inc (VRTX) , and Incyte Corp (INCY) .

Click here to see the complete history of Matthew Emmens’s form 4 insider trades.

Insider Ownership Summary of Matthew Emmens

Ticker Company Transaction Date Type of Owner
BMY Bristol-Myers Squibb Co 2017-02-21 director
VRTX Vertex Pharmaceuticals Inc 2012-11-16 director
INCY Incyte Corp 2006-05-23 director

Matthew Emmens Latest Holdings Summary

Matthew Emmens currently owns a total of 1 stock. Matthew Emmens owns 200,873 shares of Vertex Pharmaceuticals Inc (VRTX) as of November 16, 2012, with a value of $99 Million.

Latest Holdings of Matthew Emmens

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VRTX Vertex Pharmaceuticals Inc 2012-11-16 200,873 493.84 99,199,122

Holding Weightings of Matthew Emmens


Matthew Emmens Form 4 Trading Tracker

According to the SEC Form 4 filings, Matthew Emmens has made a total of 0 transactions in Vertex Pharmaceuticals Inc (VRTX) over the past 5 years. The most-recent trade in Vertex Pharmaceuticals Inc is the sale of 10,850 shares on November 16, 2012, which brought Matthew Emmens around $453,096.

Insider Trading History of Matthew Emmens

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matthew Emmens Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Matthew Emmens Ownership Network

Ownership Network List of Matthew Emmens

No Data

Ownership Network Relation of Matthew Emmens

Insider Network Chart

Matthew Emmens Owned Company Details

What does Bristol-Myers Squibb Co do?

Who are the key executives at Bristol-Myers Squibb Co?

Matthew Emmens is the director of Bristol-Myers Squibb Co. Other key executives at Bristol-Myers Squibb Co include EVP & Chief Commercial Officer Christopher S. Boerner , Chief Medical Offr. & Drug Dev. Samit Hirawat , and EVP & Corporate Affairs Cari Gallman .

Bristol-Myers Squibb Co (BMY) Insider Trades Summary

Over the past 18 months, Matthew Emmens made no insider transaction in Bristol-Myers Squibb Co (BMY). Other recent insider transactions involving Bristol-Myers Squibb Co (BMY) include a net purchase of 7,071 shares made by Christopher S. Boerner , a net purchase of 3,653 shares made by Samit Hirawat , and a net purchase of 8,500 shares made by Samuels Theodore R. Ii .

In summary, during the past 3 months, insiders sold 0 shares of Bristol-Myers Squibb Co (BMY) in total and bought 3,823 shares, with a net purchase of 3,823 shares. During the past 18 months, 700 shares of Bristol-Myers Squibb Co (BMY) were sold and 19,224 shares were bought by its insiders, resulting in a net purchase of 18,524 shares.

Bristol-Myers Squibb Co (BMY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Bristol-Myers Squibb Co Insider Transactions

No Available Data

Matthew Emmens Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew Emmens. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Matthew Emmens's mailing address is: Cambridge Ma 02139.